The continuing spread of drug-resistant tuberculosis (TB) is one of the most urgent and
difficult challenges facing global TB control. Patients who are infected with strains resistant to …

Multidrug-resistant tuberculosis (MDR-TB) presents an increasing threat to global tuberculosis
control. Many crucial management issues in MDR-TB treatment remain unanswered. We …

Background Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed
to estimate the association of treatment success and death with the use of individual drugs, …

Background Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic,
expensive, and has generally poor outcomes. We undertook an individual patient data meta-…

Background Extensively drug-resistant tuberculosis has been reported in 45 countries,
including countries with limited resources and a high burden of tuberculosis. We describe the …

Mutations at the mouse short ear (se) locus alter the formation and repair of skeletal structures
and the development of several soft tissues. Most of the developmental effects of the gene …

Background Little is known about treatment of multidrug-resistant tuberculosis (MDR-TB) in
high HIV-prevalence settings such as sub-Saharan Africa. Methodology/Principal Findings …

The clinical validity of drug susceptibility testing (DST) for pyrazinamide, ethambutol, and
second-line antituberculosis drugs is uncertain. In an individual patient data meta-analysis of …

Background . In Tomsk Oblast, Russian Federation, during the period of 1996–2000, most
previously untreated patients with tuberculosis received standardized short-course …

Rationale: We examined whether increased rifampin doses could shorten standard therapy
for tuberculosis without increased toxicity. Objectives: To assess the differences across three …